Literature DB >> 9281612

Persistent activation by and receptor reserve for an irreversible A1-adenosine receptor agonist in DDT1 MF-2 cells and in guinea pig heart.

J Zhang1, L Belardinelli, K A Jacobson, D H Otero, S P Baker.   

Abstract

The p- and m-isothiocyanate adenosine derivatives N6-[4-[[[4-[[[[2-[[[(p-(m)-isothiocyanatophenyl)amino]thiocarbonyl ]am ino]ethyl]amino]carbonyl]methyl]anilino]carbonyl]methyl]phenyl] adenosine (p- and m-DITC-ADAC) were examined for irreversible agonist effects at the A1-adenosine receptor (A1-AdoR) in DDT1 MF-2 (DDT) cells and a functional A1-AdoR response in the guinea pig isolated heart. The p- and m-DITC-ADAC inhibited (-)-isoproterenol stimulated cAMP accumulation in DDT cells in the low nanomolar range, and the maximal responses elicited by both compounds were similar to that for N6-cyclopentyladenosine. Once established, the p-DITC-ADAC-mediated inhibition of cAMP accumulation in DDT cells was not affected by the addition of the AdoR antagonist 8-cyclopentyl-1,3-dipropylxanthine (CPX). Pretreatment of DDT cells with p-DITC-ADAC (1 microM), followed by washing, reduced [3H]CPX binding to the A1-AdoR by 44% without altering the Kd value for the radioligand to the remaining receptors. The relationship between irreversible A1-AdoR occupancy by p-DITC-ADAC and inhibition of cAMP accumulation revealed a relatively large receptor reserve (64%) for the maximal response. In guinea pig isolated hearts, m-DITC-ADAC (5 microM) prolonged the stimulus to His bundle (SH) interval by 2.1-fold; this response could be prevented by the antagonist 8-cyclopentyltheophylline (5 microM). However, after the SH interval prolongation was established, extensive washout or the addition of 8-cyclopentyltheophylline had little reversal effect on the m-DITC-ADAC response. Binding of [3H]CPX to the guinea pig ventricular membranes after m-DITC-ADAC treatment and washing was reduced by 35%. The A1-AdoR occupancy response relationship for m-DITC-ADAC to prolong the SH interval indicated a small (10-20%) receptor reserve. Both p -and m-DITC-ADAC seem to be irreversible full agonists at the A1-AdoR and may prove to be useful probes to further investigate A1-AdoR structure-function relationships.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9281612      PMCID: PMC5472056          DOI: 10.1124/mol.52.3.491

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  34 in total

1.  Distinct pathways of desensitization of A1- and A2-adenosine receptors in DDT1 MF-2 cells.

Authors:  V Ramkumar; M E Olah; K A Jacobson; G L Stiles
Journal:  Mol Pharmacol       Date:  1991-11       Impact factor: 4.436

2.  Biochemical and physical analyses of newly synthesized muscarinic acetylcholine receptors in cultured embryonic chicken cardiac cells.

Authors:  D D Hunter; N M Nathanson
Journal:  J Neurosci       Date:  1986-12       Impact factor: 6.167

Review 3.  Metabolism of alpha- and beta-adrenergic receptors in vitro and in vivo.

Authors:  L C Mahan; R M McKernan; P A Insel
Journal:  Annu Rev Pharmacol Toxicol       Date:  1987       Impact factor: 13.820

Review 4.  Cloned adenosine A3 receptors: pharmacological properties, species differences and receptor functions.

Authors:  J Linden
Journal:  Trends Pharmacol Sci       Date:  1994-08       Impact factor: 14.819

5.  Agonist photoaffinity labeling of A1 adenosine receptors: persistent activation reveals spare receptors.

Authors:  M J Lohse; K N Klotz; U Schwabe
Journal:  Mol Pharmacol       Date:  1986-10       Impact factor: 4.436

6.  Differences in muscarinic receptor reserve for inhibition of adenylate cyclase and stimulation of phosphoinositide hydrolysis in chick heart cells.

Authors:  J H Brown; D Goldstein
Journal:  Mol Pharmacol       Date:  1986-12       Impact factor: 4.436

7.  Mechanism of A2 adenosine receptor activation. I. Blockade of A2 adenosine receptors by photoaffinity labeling.

Authors:  M J Lohse; K N Klotz; U Schwabe
Journal:  Mol Pharmacol       Date:  1991-04       Impact factor: 4.436

8.  Molecular cloning and characterization of an adenosine receptor: the A3 adenosine receptor.

Authors:  Q Y Zhou; C Li; M E Olah; R A Johnson; G L Stiles; O Civelli
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

Review 9.  Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.

Authors:  K A Jacobson; P J van Galen; M Williams
Journal:  J Med Chem       Date:  1992-02-07       Impact factor: 7.446

10.  Electrophilic derivatives of purines as irreversible inhibitors of A1 adenosine receptors.

Authors:  K A Jacobson; S Barone; U Kammula; G L Stiles
Journal:  J Med Chem       Date:  1989-05       Impact factor: 7.446

View more
  6 in total

1.  Differential A(1)-adenosine receptor reserve for inhibition of cyclic AMP accumulation and G-protein activation in DDT(1) MF-2 cells.

Authors:  S P Baker; P J Scammells; L Belardinelli
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

2.  Functionalized congeners of 1,4-dihydropyridines as antagonist molecular probes for A3 adenosine receptors.

Authors:  A H Li; L Chang; X d Ji; N Melman; K A Jacobson
Journal:  Bioconjug Chem       Date:  1999 Jul-Aug       Impact factor: 4.774

Review 3.  Adenosine and ischemic preconditioning.

Authors:  B T Liang; K A Jacobson
Journal:  Curr Pharm Des       Date:  1999-12       Impact factor: 3.116

4.  Development of subtype-selective covalent ligands for the adenosine A2B receptor by tuning the reactive group.

Authors:  Bert L H Beerkens; Xuesong Wang; Maria Avgeropoulou; Lisa N Adistia; Jacobus P D van Veldhoven; Willem Jespers; Rongfang Liu; Laura H Heitman; Adriaan P IJzerman; Daan van der Es
Journal:  RSC Med Chem       Date:  2022-06-21

Review 5.  Chemical Probes for the Adenosine Receptors.

Authors:  Stephanie Federico; Lucia Lassiani; Giampiero Spalluto
Journal:  Pharmaceuticals (Basel)       Date:  2019-11-12

Review 6.  Molecular probes for the human adenosine receptors.

Authors:  Xue Yang; Laura H Heitman; Adriaan P IJzerman; Daan van der Es
Journal:  Purinergic Signal       Date:  2020-12-12       Impact factor: 3.765

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.